Business

Algorae Pharmaceuticals (ASX:1AI) has announced the appointment of experienced pharmaceutical executive Vishal Shah as its chief commercial officer.

Race Oncology (ASX:RAC) has announced the site activation of Southside Cancer Care Centre in Sydney after receiving governance approval enabling the commencement of patient enrolment for its Phase 1 clinical trial of RC220 in combination with doxorubicin.

Percheron Therapeutics (ASX:PER) has updated shareholders on its actions following the disappointing result in the Phase 2b trial of its avicursen in non-ambulant boys with Duchenne muscular dystrophy.

Microbiome health company Biome Australia (ASX:BIO) has announced that its wholly owned subsidiary, Biome Australia Trading, has entered into a $5 million secured debt facility with National Australia Bank.

Researchers at The University of Queensland have found that improving the function of the gut microbiome may delay the onset of type 1 diabetes.

Cyclopharm (ASX:CYC) has announced that the US commercial sales of Technegas have now exceeded $US1 million following its launch last year.

Medical technology company Artrya (ASXAYA) has announced a commercial contract with Lumus Imaging for the use of the Salix Coronary Anatomy platform.

BioNSW has launched its inaugural BioInvest Catalyst event. The organisation said the three-part event series aims to foster deeper engagement between investors and life science entrepreneurs.

The Melbourne scientists who developed OMJJARA, Professor Andrew Wilks and Dr Chris Burns, said, “Today’s PBS milestone is our ‘full circle’ moment."

Opthea (ASX:OPT) has announced it will discontinue clinical trials involving its sozinibercept in combination with other therapies for treating wet age-related macular degeneration.

AusBiotech says that while the 2025-26 Budget did not include significant new commitments for Australia’s life sciences sector, it remains steadfast in its advocacy to unlock this critical sector's full potential.

Mesoblast (ASX:MSB) has announced that its FDA-approved Ryoncil (remestemcel-L) mesenchymal stromal cell therapy is now available for purchase in the US.